How do I buy Vertex Pharmaceuticals (VRTX) stock?

Buying Vertex Pharmaceuticals (VRTX) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "VRTX", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy VRTX by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if VRTX is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Vertex Pharmaceuticals (VRTX) Stock

Q: What is the minimum investment for VRTX on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Vertex Pharmaceuticals from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · VRTX

Trade VRTX

Key stats

Market cap: $140.20B
Price / Earnings ratio: 31.8x
EPS (TTM): $17.33
Volume: Loading
52-week high: $568.67
52-week low: $403.16
EPS vs analyst estimate: +10.3%Q3 FY25 · $4.80 vs $4.35

Source: third-party data provider, as of November 4, 2026

EPS estimate: analyst consensus

Compare with VRTX

Technical indicators

RSI 14: 53.12
MACD 12/26/9: 7.55
EMA 9 of MACD: 3.83
MACD histogram: 3.72
SMA 50: $522.98; Price above SMA 50
EMA 50: $518.21; Price above EMA 50
SMA 200: $480.23; Price above SMA 200
EMA 200: $485.03; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 3, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 12 analyst ratings

Strong Sell0

Sell0

Hold1

Buy11

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

14B10B5B0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

31B20B10B0

Revenue to Profit

2025

$12.0B

Revenue

$0.0

Cost of revenue

$10.3B

Gross profit

$0.0

Operating expenses

$4.0B

Net income

Earnings

EPS forecast

Actual EPS

$4.80

$4.35

Q3FY25

$4.84

Q4FY25

$4.53

Q1FY26

$4.21

Q2FY26

$4.35

Q3FY26

The market is expecting earnings per share of $4.35 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.

SectorHealthcare

IndustryBiotechnology

Employees6,400

CEODr. Reshma Kewalramani FASN, M.D.

IPO DateJul 24, 1991

HeadquartersBoston, MA

Key Executives

Name	Title	Year Born
Dr. Reshma Kewalramani FASN, M.D.	CEO, President & Director	1973
Dr. Jeffrey Marc Leiden M.D., Ph.D.	Executive Chairman	1956
Mr. Charles F. Wagner Jr.	Executive VP, COO & CFO	1968
Mr. Amit K. Sachdev J.D.	Executive VP & Chief Patient and External Affairs Officer	1968
Dr. Ourania Tatsis Ph.D.	Executive VP & Chief Product Affairs Officer	1970
Dr. Carmen Bozic M.D.	Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer	1963
Dr. Mark Bunnage D.Phil	Executive VP & Chief Scientific Officer	1969
Ms. Susie Lisa C.F.A.	Senior Vice President of Investor Relations	—
Ms. Joy Liu J.D.	EVP, Chief Legal Officer & Corporate Secretary	1978
Ms. Nina Devlin	Senior VP & Chief Communications Officer	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-3.1	+7.1
2022	+9.2	-6.4	+13.1	+2.7	+2.6	+4.6	-2.4	+2.9	-0.2	+4.9	+0.7	-10.0
2023	+13.0	-8.5	+8.2	+7.7	-6.2	+8.7	+1.4	+0.2	-1.0	+4.1	-3.9	+15.9
2024	+5.5	-3.0	-3.4	-6.6	+13.2	-0.3	+5.2	-2.0	-2.2	+1.3	-0.6	-13.5
2025	+13.8	+2.0	+0.3	+5.1	-11.4	-0.1	+1.0	-15.4	-2.3	+5.3	+1.8	+6.5
2026	+3.9	+5.3	-8.1	-4.4	+5.6	+13.3	-4.2	+15.7	-4.5	+10.3	-4.0

Stocks in the same sector

Abeona Therapeutics Inc.

Agios Pharmaceuticals, Inc.

FAQ

Buying Vertex Pharmaceuticals (VRTX) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "VRTX", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy VRTX by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Vertex Pharmaceuticals from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Vertex Pharmaceuticals (VRTX) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track VRTX's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Vertex Pharmaceuticals (VRTX) Stock

Key stats

Compare with VRTX

Recent news

Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex: 3 Key Takeaways for Long-Term Investors

Vertex: 3 Key Takeaways for Long-Term Investors

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex: 3 Key Takeaways for Long-Term Investors

Vertex: 3 Key Takeaways for Long-Term Investors

Vertex Pharmaceuticals Q3 Earnings Call Highlights

Vertex Pharmaceuticals Q3 Earnings Call Highlights

Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates

Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance Hike

Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance Hike

Vertex Reports Third Quarter 2026 Financial Results

Vertex Reports Third Quarter 2026 Financial Results

About Vertex Pharmaceuticals

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade